期刊文献+

慢性阻塞性肺病患者肺炎衣原体感染临床分析 被引量:8

Chlamydia pneumoniae infection in patients with chronic obstructive pulmonary disease clinical analysis
下载PDF
导出
摘要 目的 调查慢性肺炎衣原体(Cpn)感染和慢性阻塞性肺病(COPD)之间可能的相关性.方法 选取来我院就诊的COPD急性加重期患者60例,COPD稳定期患者40例,以及同期来院参加健康体检的老年人50例(对照组),测定其第一秒用力呼气容积(FEV1)、用力肺活量(FVC)和圣乔治呼吸问卷(SGRQ)评分.用ELISA法检测Cpn抗体(IgA,IgG和IgM).结果 COPD急性加重期患者的Cpn-IgM抗体检出率显著高于对照组(P<0.01),COPD急性加重期组和COPD稳定期组Cpn-IgA和IgG抗体的检出率均显著高于对照组(P<0.01).阿奇霉素治疗后所有COPD患者的临床症状均有显著改善:SGRQ记分和FEV1占预计值%显著增加,仅COPD急性加重期患者Cpn-IgM滴度显著下降(P<0.01).结论 慢性Cpn感染可能是COPD发展的危险因素. Objective To investigate the possible association between chronic infection of Chlamydia pneumoniae(Cpn) and chronic obstructive pulmonary disease (COPD).Methods Select to our hospital treatment in 60 patients with acute exacerbations of COPD,40 cases of patients with stable stage of COPD,as well as 50 cases of elderly people to participate in healthy physical examination to the same period(control group),Determination of the FEV1,FVC and St.George Respiratory Questionnaire (SGRQ) score.Detection of Cpn antibody (IgA,IgG and IgM) by ELISA.Results The detection rate of Cpn-IgM in acute exacerbations of COPD group were significantly higher than the control group (P < 0.01),the detection rate of Cpn-IgA and Cpn-IgG in acute exacerbations of COPD and stable stage of COPD group were significantly higher than the control group(P < 0.01).After azithromycin treatment,the clinical symptoms of all patients with COPD were improved significantly.SGRQ scores and FEV1/Pre (%) were increased significantly,and meanwhile,only the titer of Cpn-IgM was decreased significantly (P < 0.01) in acute exacerbations of COPD group.Conclusion The results suggest that chronic Cpn infection may be a risk factor for the development of COPD.
出处 《临床内科杂志》 CAS 2013年第10期679-681,共3页 Journal of Clinical Internal Medicine
基金 上海市金山区卫生局科研基金资助项目(编号:2010-07)
关键词 肺炎衣原体 慢性阻塞性肺疾病 阿奇霉素 Chlamydia pneumoniae Chronic obstructive pulmonary disease Azithromycin
  • 相关文献

参考文献14

  • 1Gmneberg DA,Chung KF.Models of chronic obstructive pulmonary disease.Respir Res,2004,5:18.
  • 2Brandén E,Koyi H,Gnarpe J,et al.Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD.Respir Med,2005,99:20-26.
  • 3中华医学会呼吸病学分会慢性阻塞性肺疾病学组.COPD诊治指南(2007年修订版).继续医学教育,2008,:31-42.
  • 4Fan P,Dong F,Huang Y,et al.Chiamydia pneumoniae secrection of a proteases-like activity factor for degrading host cell transcription factor required for major histocompatibility complex antigen expresion.Infection Immunity,2002,70:345-349.
  • 5Brandén E,Koyi H,Gnarpe J,et al.Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection.Scand J Infect Dis,2004,36:811-816.
  • 6Medinas Amorós M,Mas-Tous C,Renom-Sotorra F,et al.Health-related quality of life is associated with COPD severity:a comparison between the GOLD staging and the BODE index.Chron Respir Dis,2009,6:75-80.
  • 7Miyashita N.Chlamydia pneumoniae infection.Kekaku,2006,81:581-588.
  • 8Krull M,Bockstaller P,Wupermann FN,et al.Mechanisms of Chlamydophila pneumoniae mediated GM-CSF release in human bronchial epithelial cells.Am J Respir Cell Molto Biology,2006,3:375-382.
  • 9Brandén E,Koyi H,Gnarpe J,et al.Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD.Respir Med,2005 ;99:20-26.
  • 10Daenas C,Hatziefthimiou AA,Gourgoulianis KI,et al.Azithromycin has a direct relaxant effect on precontracted airway smooth muscle.Eur J Phamacol,2006,553:280-287.

二级参考文献11

  • 1Laizo A:Chronie obstructive pulmonary disease-A review[J].Rev Port Pneumol,2009,15(6):1157-1166.
  • 2Diederen BM,van der Valk PD,Kluytmans JA,et al.The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease[J 1.Eur Respir J,2007,30 (2):240-244.
  • 3Tashkin DP,Pearle J,lezzoni D,et al.Formoterol and tiotropium compared with tiotropium alone for treatment o[COPD[J].COPD,2009,6(1):17-25.
  • 4Lee PI,Wu MH,Huang LM,et al.An open,randomized,comparative study of clarithromycin and erythromycin in the treatment of children with community-acquired pneumonia[J].J Microbiol Immunol Infect.2008,41(1),54-61.
  • 5Brand n E,Gnarpe J,Hillerdal G,et al.Detection of Chlamydia pneumoniae on cytospin preparations from bronchoalveolar layage in COPD patients and in lung tissue from advanced emphysema[J].Int J Chron Obstruct Pulmon Dis,2007,2(4)..643-650.
  • 6Heredia JL.Tiotropium bromide:an update[J].Open Respir Med J,2009,3:43-52.
  • 7Trevethick M,Clarke N,Strawbridge M,et al.Inhaled muscarinic antagonists for COPD--does an anti-inflammatory mechanism really play a role[J].Curr Opin Pharmacol,2009,9 (3):250-255.
  • 8Wales D,Woodhead M.The anti-inflammatory effects of macrolides[J].Thorax,1999,54(Suppl 2):S58-62.
  • 9van Zandbergen G,Gieffers J,Kothe H,et al.Chlamydia pneumoniae multiply in neutrophil granulocytes and delay their spontaneous apoptosis[J].J Immunol,2004,172 (3):1768-1776.
  • 10Lieberman D,Lieberman D,Printz S,et al.Atypical pathogen infection in adults with acute exacerbation of bronchial asthma[J].Am J Respir Crit Care Med,2003,167(3):406-410.

共引文献20

同被引文献42

引证文献8

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部